A vulnerability was discovered in the Remisol Advance v2.0.12.1 and below for the Normand Message Server. On installation, the permissions set by Remisol Advance allow non-privileged users to overwrite and/or manipulate executables and libraries that run as the elevated SYSTEM user on Windows.
Conclusion & alert: CVE-2022-26235 is rated Low Risk (34/100): CVSS High severity, with low exploitation likelihood (EPSS 0.18%). Mandatory action: Monitor for updates and reassess as exploit intelligence or EPSS changes.
Risk is dynamic; we continuously reassess and refresh what is shown on this page as upstream context changes.
EPSS lead: Daily EPSS estimates relative likelihood of exploitation; percentile ranks this CVE among scored vulnerabilities (higher = more severe relative rank).
| # | Date | Old EPSS score | New EPSS score | Delta (New - Old) |
|---|---|---|---|---|
| 1 | 2026-06-15 | 0.03% | 0.18% | +0.15% |
| 2 | 2025-10-12 | 0.05% | 0.03% | -0.02% |
| 3 | 2025-08-02 | — | 0.05% | — |
Full EPSS history (7 records total)
CVSS metrics for this CVE.
| Base score | Version | Severity | Vector | Exploitability | Impact | Score source |
|---|---|---|---|---|---|---|
| 7.8 | 3.1 | HIGH |
|
1.8 | 5.9 | [email protected] |
| Vendor | Product | Version | Raw CPE |
|---|---|---|---|
| beckmancoulter | remisol_advance | <= 2.0.12.1 | cpe:2.3:a:beckmancoulter:remisol_advance:*:*:*:*:*:*:*:* |
| URL | Tags |
|---|---|
| https://pastebin.com/amgw9pE7 | Third Party Advisory |
| https://www.beckmancoulter.com/products/clinical-information-management-tools/remisol-advance | Product Vendor Advisory |